BOTHELL, Wash., March 10, 2025--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ...

IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study ...

Plasma stability and in vivo analyses confirmed that alphalex conjugates selectively deliver microtubule inhibitors to tumor ... following a topoisomerase-1 (TOP1)-based ADC The antigen-agnostic ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

CBX-12 is a first-in-class PDC that utilizes Cybrexa's proprietary alphalex technology to enhance the intracellular delivery of exatecan, a highly potent, well-established TOP1 inhibitor. This trial ...

Presented data highlighting preclinical efficacy for IM-1021 and a differentiated profile for HC74, Immunome’s proprietary TOP1 ADC payload ... a gamma secretase inhibitor which is currently ...